Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRROR: Ofatumumab in RRMS
NCT01457924Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2011
- Primary completion
- Aug 2013
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of ofatumumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by GSK. Started Nov 2011; status: completed.
02
Drugs
ofatumumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01457924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01457924.